bleomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 4742 11056-06-7

Description:

MoleculeDescription

Synonyms:

  • bleomycin
  • bleomycins
  • bleomycin sulfate
  • bleomycin hydrochloride
  • bleomycin HCl
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
  • Molecular weight: 2841.07
  • Formula: C110H168N37O42S5
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 688.97
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.35 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.43 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.26 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.90 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 20 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
July 31, 1973 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 452.82 28.40 253 9364 158096 90460734
Hepatitis B reactivation 273.22 28.40 67 9550 3907 90614923
Neutropenia 242.13 28.40 196 9421 224708 90394122
Pulmonary toxicity 206.66 28.40 68 9549 11463 90607367
Acute hepatic failure 172.31 28.40 71 9546 22490 90596340
Second primary malignancy 157.44 28.40 54 9563 10324 90608506
Ovarian germ cell teratoma 148.12 28.40 22 9595 69 90618761
Teratoma 124.63 28.40 21 9596 172 90618658
Candida infection 115.18 28.40 61 9556 33996 90584834
Streptococcal sepsis 110.27 28.40 32 9585 3552 90615278
Interstitial lung disease 109.22 28.40 79 9538 76326 90542504
Nail bed inflammation 101.96 28.40 26 9591 1775 90617055
Nasal mucosal disorder 101.17 28.40 26 9591 1831 90616999
Pseudomonal sepsis 100.27 28.40 31 9586 4271 90614559
Pancytopenia 96.92 28.40 89 9528 120174 90498656
Acute myeloid leukaemia 96.34 28.40 46 9571 20594 90598236
Mucosal inflammation 94.93 28.40 65 9552 57560 90561270
Off label use 93.73 28.40 292 9325 1101960 89516870
Brain oedema 91.19 28.40 42 9575 17343 90601487
Metastases to lymph nodes 89.94 28.40 37 9580 11652 90607178
Disease progression 89.31 28.40 96 9521 156519 90462311
Abdominal compartment syndrome 84.32 28.40 19 9598 764 90618066
Deafness 83.76 28.40 43 9574 22471 90596359
Teratoma benign 83.55 28.40 13 9604 60 90618770
Myelodysplastic syndrome 80.89 28.40 41 9576 20862 90597968
Bone marrow failure 79.69 28.40 47 9570 32174 90586656
Respiratory failure 79.04 28.40 79 9538 118339 90500491
Myelosuppression 77.90 28.40 56 9561 53535 90565295
Sepsis 72.08 28.40 92 9525 179722 90439108
Anaemia 69.72 28.40 130 9487 352672 90266158
Vascular device infection 69.40 28.40 31 9586 11921 90606909
Restlessness 67.75 28.40 44 9573 35676 90583154
Metastases to central nervous system 66.69 28.40 34 9583 17508 90601322
Varicose vein 66.07 28.40 26 9591 7301 90611529
Paronychia 63.83 28.40 26 9591 7980 90610850
Acute respiratory distress syndrome 61.04 28.40 38 9579 28648 90590182
Chloroma 60.94 28.40 12 9605 248 90618582
Cutaneous calcification 57.20 28.40 11 9606 200 90618630
Synovial sarcoma 55.86 28.40 9 9608 54 90618776
Febrile bone marrow aplasia 55.72 28.40 25 9592 9713 90609117
Necrotising gastritis 54.17 28.40 9 9608 67 90618763
Thrombocytopenia 53.03 28.40 86 9531 208639 90410191
Premature baby 52.80 28.40 33 9584 25044 90593786
Respiratory symptom 52.54 28.40 19 9598 4233 90614597
Congestive cardiomyopathy 52.26 28.40 22 9595 7332 90611498
Drug resistance 51.67 28.40 35 9582 30414 90588416
Malignant neoplasm progression 51.42 28.40 60 9557 106810 90512020
Pleural effusion 50.79 28.40 61 9556 111930 90506900
Basal ganglion degeneration 50.69 28.40 11 9606 371 90618459
Leukaemia 49.56 28.40 19 9598 4973 90613857
Pain 49.56 28.40 22 9595 996319 89622511
Primary immunodeficiency syndrome 49.51 28.40 8 9609 49 90618781
Combined immunodeficiency 47.71 28.40 9 9608 147 90618683
Sarcoidosis 47.41 28.40 23 9594 10650 90608180
Tissue infiltration 46.51 28.40 12 9605 858 90617972
Aplasia 46.21 28.40 17 9600 3974 90614856
Premature menopause 45.96 28.40 13 9604 1316 90617514
Pleuroparenchymal fibroelastosis 45.04 28.40 9 9608 201 90618629
Peripheral sensory neuropathy 44.33 28.40 21 9596 9229 90609601
Haematotoxicity 43.91 28.40 23 9594 12512 90606318
Mucoepidermoid carcinoma of salivary gland 43.89 28.40 7 9610 39 90618791
Cytomegalovirus infection 43.77 28.40 30 9587 26572 90592258
Anaesthesia 43.19 28.40 10 9607 454 90618376
Neuropathy peripheral 42.59 28.40 62 9555 136908 90481922
Uterine enlargement 41.31 28.40 12 9605 1336 90617494
Posterior reversible encephalopathy syndrome 41.09 28.40 27 9590 22312 90596518
Rash 40.46 28.40 17 9600 796083 89822747
Flagellate dermatitis 40.46 28.40 8 9609 169 90618661
Skin fissures 40.35 28.40 26 9591 20783 90598047
Exposure during pregnancy 39.90 28.40 82 9535 238328 90380502
Haemophagocytic lymphohistiocytosis 39.40 28.40 23 9594 15436 90603394
Vulvovaginal inflammation 39.15 28.40 11 9606 1087 90617743
Product use in unapproved indication 38.96 28.40 100 9517 336136 90282694
Foetal exposure during pregnancy 38.91 28.40 34 9583 42941 90575889
Traumatic lung injury 37.91 28.40 12 9605 1784 90617046
Psychogenic seizure 36.55 28.40 12 9605 2004 90616826
Hyperpyrexia 36.38 28.40 15 9602 4746 90614084
Inguinal hernia 36.08 28.40 12 9605 2086 90616744
Lymphopenia 35.75 28.40 25 9592 22856 90595974
Tumour lysis syndrome 34.95 28.40 19 9598 11133 90607697
Cardiotoxicity 34.57 28.40 19 9598 11370 90607460
Transdifferentiation of neoplasm 33.58 28.40 5 9612 16 90618814
Weight increased 33.36 28.40 3 9614 417924 90200906
Encephalitis viral 33.26 28.40 11 9606 1878 90616952
Infusion related reaction 33.24 28.40 3 9614 416777 90202053
Lymphadenopathy 33.22 28.40 32 9585 45743 90573087
Capillary leak syndrome 32.83 28.40 12 9605 2755 90616075
Hepatitis G 32.47 28.40 6 9611 87 90618743
Septic shock 32.01 28.40 42 9575 84118 90534712
Hypochromic anaemia 31.76 28.40 11 9606 2160 90616670
Dysaesthesia 31.69 28.40 14 9603 5241 90613589
Disease recurrence 30.54 28.40 28 9589 37625 90581205
Pneumonitis 30.41 28.40 30 9587 44140 90574690
Peripheral swelling 30.34 28.40 4 9613 413102 90205728
Neurological decompensation 30.08 28.40 12 9605 3489 90615341
Pneumocystis jirovecii pneumonia 30.05 28.40 22 9595 21594 90597236
Acute promyelocytic leukaemia 30.00 28.40 9 9608 1120 90617710
Meningitis streptococcal 29.81 28.40 6 9611 139 90618691
Nasopharyngitis 29.76 28.40 4 9613 407100 90211730
Therapy partial responder 29.67 28.40 22 9595 22021 90596809
Pulmonary fibrosis 29.61 28.40 46 9571 107457 90511373
Monoplegia 29.52 28.40 12 9605 3662 90615168
Acute lymphocytic leukaemia 28.85 28.40 11 9606 2837 90615993
Swelling 28.62 28.40 5 9612 419053 90199777

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 446.28 21.74 382 11208 185321 42424424
Second primary malignancy 389.54 21.74 132 11458 9443 42600302
Pulmonary toxicity 327.36 21.74 113 11477 8542 42601203
Acute myeloid leukaemia 316.09 21.74 143 11447 22113 42587632
Azoospermia 168.20 21.74 37 11553 497 42609248
Pneumonitis 147.12 21.74 108 11482 41610 42568135
Pulmonary fibrosis 141.66 21.74 89 11501 26592 42583153
Neutropenia 130.97 21.74 211 11379 199220 42410525
Interstitial lung disease 130.42 21.74 132 11458 78330 42531415
Acute respiratory distress syndrome 120.01 21.74 84 11506 30024 42579721
Flagellate dermatitis 113.67 21.74 21 11569 106 42609639
Myelodysplastic syndrome 108.65 21.74 71 11519 22674 42587071
Cardiotoxicity 78.46 21.74 39 11551 7406 42602339
Pneumomediastinum 77.89 21.74 30 11560 3086 42606659
Haematotoxicity 74.73 21.74 43 11547 10942 42598803
Respiratory failure 73.77 21.74 128 11462 128004 42481741
Endocarditis noninfective 72.33 21.74 15 11575 149 42609596
Bone marrow failure 70.68 21.74 64 11526 33029 42576716
Traumatic lung injury 68.73 21.74 22 11568 1310 42608435
Chronic myeloid leukaemia 58.77 21.74 23 11567 2469 42607276
Papillary thyroid cancer 58.12 21.74 17 11573 746 42608999
Myositis 58.09 21.74 41 11549 14825 42594920
Scleroderma 54.95 21.74 20 11570 1758 42607987
Off label use 54.71 21.74 327 11263 638008 41971737
Cytomegalovirus chorioretinitis 54.11 21.74 26 11564 4585 42605160
Osteonecrosis 53.45 21.74 40 11550 15825 42593920
Pneumocystis jirovecii pneumonia 52.39 21.74 48 11542 25133 42584612
Thrombocytopenia 50.43 21.74 139 11451 190140 42419605
Neoplasm progression 48.47 21.74 49 11541 28951 42580794
Ischaemic stroke 47.46 21.74 43 11547 22190 42587555
Disease progression 47.40 21.74 114 11476 143542 42466203
Coronary artery thrombosis 46.61 21.74 19 11571 2267 42607478
Vena cava thrombosis 46.17 21.74 17 11573 1544 42608201
Testicular disorder 46.16 21.74 15 11575 937 42608808
Pyrexia 45.25 21.74 219 11371 393823 42215922
Teratoma 45.02 21.74 8 11582 31 42609714
Lung disorder 44.75 21.74 60 11530 47863 42561882
Malignant neoplasm progression 44.67 21.74 94 11496 108306 42501439
Pneumothorax 43.46 21.74 42 11548 23501 42586244
Leukopenia 43.38 21.74 75 11515 74671 42535074
Pulmonary embolism 42.80 21.74 98 11492 119514 42490231
Acute myocardial infarction 41.38 21.74 64 11526 58101 42551644
Chloroma 40.21 21.74 12 11578 565 42609180
Subcutaneous emphysema 37.59 21.74 15 11575 1694 42608051
Premature ageing 37.50 21.74 8 11582 92 42609653
Fall 37.28 21.74 9 11581 234511 42375234
Blindness 36.87 21.74 34 11556 17944 42591801
Autoimmune neutropenia 36.42 21.74 10 11580 348 42609397
Peripheral sensory neuropathy 36.17 21.74 25 11565 8737 42601008
Carotid artery thrombosis 35.75 21.74 10 11580 373 42609372
Taeniasis 35.57 21.74 7 11583 52 42609693
Deafness 35.32 21.74 29 11561 13111 42596634
Pancytopenia 35.18 21.74 90 11500 117653 42492092
Vascular access site occlusion 35.11 21.74 7 11583 56 42609689
Asthenospermia 33.99 21.74 7 11583 67 42609678
Vocal cord inflammation 33.99 21.74 7 11583 67 42609678
Therapy partial responder 33.76 21.74 34 11556 19987 42589758
Mucosal inflammation 33.27 21.74 53 11537 49321 42560424
Pain 32.47 21.74 13 11577 244835 42364910
Testicular cancer metastatic 31.95 21.74 7 11583 92 42609653
Blood pressure decreased 31.85 21.74 57 11533 58275 42551470
Lung infiltration 31.72 21.74 28 11562 13961 42595784
Abnormal DNA methylation 31.28 21.74 5 11585 8 42609737
Paternal exposure timing unspecified 30.44 21.74 6 11584 45 42609700
Arterial thrombosis 30.30 21.74 13 11577 1763 42607982
Rash 30.28 21.74 19 11571 276935 42332810
Testicular malignant teratoma 30.24 21.74 5 11585 11 42609734
Cerebral infarction 29.04 21.74 39 11551 31130 42578615
Dizziness 28.80 21.74 16 11574 249238 42360507
Ichthyosis 28.74 21.74 7 11583 150 42609595
Product dose omission issue 28.64 21.74 4 11586 154361 42455384
Death 28.59 21.74 53 11537 471132 42138613
Neutropenic sepsis 28.59 21.74 28 11562 15918 42593827
Choriocarcinoma 28.43 21.74 5 11585 18 42609727
Septic shock 28.33 21.74 71 11519 91601 42518144
Osteosarcoma 28.31 21.74 8 11582 310 42609435
Peripheral artery thrombosis 28.03 21.74 14 11576 2683 42607062
Embolism arterial 27.97 21.74 10 11580 835 42608910
Pneumonia salmonella 27.89 21.74 6 11584 72 42609673
Organising pneumonia 27.64 21.74 20 11570 7512 42602233
Fatigue 27.32 21.74 48 11542 435593 42174152
Product use in unapproved indication 26.70 21.74 110 11480 184346 42425399
Malignant transformation 26.54 21.74 10 11580 968 42608777
Splenic infarction 26.39 21.74 13 11577 2418 42607327
Vasogenic cerebral oedema 25.98 21.74 10 11580 1026 42608719
Arthralgia 25.45 21.74 12 11578 205226 42404519
Somnolence 25.38 21.74 4 11586 141101 42468644
Trisomy 13 25.18 21.74 4 11586 6 42609739
Cardiac dysfunction 24.98 21.74 14 11576 3385 42606360
Subdural haemorrhage 24.59 21.74 14 11576 3487 42606258
Febrile bone marrow aplasia 24.33 21.74 21 11569 10160 42599585
Guillain-Barre syndrome 23.76 21.74 18 11572 7245 42602500
Peripheral nerve injury 23.67 21.74 7 11583 319 42609426
Diarrhoea 23.62 21.74 57 11533 460792 42148953
Spindle cell sarcoma 23.60 21.74 6 11584 154 42609591
Diaphragm muscle weakness 23.39 21.74 6 11584 160 42609585
Heart disease congenital 22.78 21.74 10 11580 1432 42608313
Inclusion body myositis 22.60 21.74 5 11585 69 42609676
Hair growth abnormal 22.58 21.74 9 11581 1013 42608732
Cerebral artery stenosis 22.58 21.74 7 11583 375 42609370
Cerebral venous thrombosis 22.42 21.74 9 11581 1032 42608713
Renal salt-wasting syndrome 21.99 21.74 7 11583 409 42609336

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 897.47 21.12 604 18903 316163 110253629
Second primary malignancy 521.93 21.12 173 19334 17895 110551897
Pulmonary toxicity 469.27 21.12 159 19348 17587 110552205
Acute myeloid leukaemia 435.80 21.12 185 19322 37925 110531867
Neutropenia 355.13 21.12 381 19126 374239 110195553
Interstitial lung disease 242.57 21.12 199 19308 139135 110430657
Myelodysplastic syndrome 197.76 21.12 107 19400 37377 110532415
Acute respiratory distress syndrome 185.37 21.12 116 19391 53082 110516710
Pneumonitis 180.56 21.12 131 19376 76400 110493392
Respiratory failure 157.70 21.12 192 19315 215140 110354652
Teratoma 154.45 21.12 27 19480 158 110569634
Flagellate dermatitis 153.01 21.12 29 19478 281 110569511
Ovarian germ cell teratoma 137.67 21.12 22 19485 66 110569726
Pancytopenia 137.65 21.12 177 19330 209436 110360356
Haematotoxicity 136.36 21.12 69 19438 21013 110548779
Bone marrow failure 134.10 21.12 98 19409 57750 110512042
Pulmonary fibrosis 127.83 21.12 121 19386 101921 110467871
Disease progression 126.85 21.12 184 19323 243850 110325942
Thrombocytopenia 123.74 21.12 221 19286 348664 110221128
Malignant neoplasm progression 113.93 21.12 147 19360 174420 110395372
Off label use 106.01 21.12 532 18975 1499653 109070139
Mucosal inflammation 105.43 21.12 106 19401 96035 110473757
Pneumocystis jirovecii pneumonia 104.97 21.12 75 19432 42660 110527132
Teratoma benign 102.79 21.12 17 19490 67 110569725
Pneumomediastinum 98.19 21.12 36 19471 5000 110564792
Nasal mucosal disorder 92.10 21.12 27 19480 1856 110567936
Traumatic lung injury 91.99 21.12 29 19478 2548 110567244
Brain oedema 91.50 21.12 61 19446 31037 110538755
Nail bed inflammation 90.09 21.12 27 19480 2003 110567789
Candida infection 88.54 21.12 71 19436 47938 110521854
Chloroma 87.96 21.12 22 19485 826 110568966
Peripheral sensory neuropathy 86.23 21.12 47 19460 16633 110553159
Pain 85.46 21.12 31 19476 954924 109614868
Streptococcal sepsis 83.39 21.12 32 19475 5040 110564752
Chronic myeloid leukaemia 81.29 21.12 30 19477 4243 110565549
Cardiotoxicity 77.52 21.12 44 19463 16837 110552955
Metastases to lymph nodes 73.97 21.12 41 19466 14991 110554801
Endocarditis noninfective 69.52 21.12 15 19492 290 110569502
Myelosuppression 68.75 21.12 84 19423 94256 110475536
Therapy partial responder 68.74 21.12 55 19452 37006 110532786
Leukopenia 68.38 21.12 106 19401 148685 110421107
Abdominal compartment syndrome 65.95 21.12 21 19486 1906 110567886
Pseudomonal sepsis 65.57 21.12 32 19475 9014 110560778
Pyrexia 64.05 21.12 320 19187 897945 109671847
Sarcoidosis 63.79 21.12 35 19472 12544 110557248
Rash 63.33 21.12 33 19474 820931 109748861
Metastases to central nervous system 62.92 21.12 43 19464 22774 110547018
Pneumothorax 62.55 21.12 51 19456 35234 110534558
Joint swelling 59.51 21.12 5 19502 442840 110126952
Sepsis 59.05 21.12 158 19349 327188 110242604
Osteonecrosis 58.20 21.12 48 19459 33693 110536099
Anaemia 58.19 21.12 220 19287 546866 110022926
Varicose vein 57.77 21.12 27 19480 6913 110562879
Septic shock 57.27 21.12 101 19406 157427 110412365
Pleuroparenchymal fibroelastosis 56.14 21.12 13 19494 350 110569442
Peripheral swelling 55.86 21.12 4 19503 404030 110165762
Neuropathy peripheral 55.20 21.12 107 19400 179170 110390622
Azoospermia 54.95 21.12 12 19495 246 110569546
Necrotising gastritis 54.93 21.12 10 19497 76 110569716
Product use in unapproved indication 53.55 21.12 187 19320 447190 110122602
Febrile bone marrow aplasia 53.16 21.12 35 19472 17430 110552362
Congestive cardiomyopathy 52.01 21.12 32 19475 14187 110555605
Myelitis 51.85 21.12 20 19487 3193 110566599
Neoplasm progression 51.13 21.12 60 19447 64535 110505257
Cutaneous calcification 51.01 21.12 11 19496 212 110569580
Weight increased 50.63 21.12 7 19500 419637 110150155
Acute promyelocytic leukaemia 50.13 21.12 17 19490 1879 110567913
Subcutaneous emphysema 48.63 21.12 18 19489 2566 110567226
Paronychia 48.51 21.12 28 19479 11053 110558739
Coronary artery thrombosis 48.13 21.12 19 19488 3225 110566567
Synovial sarcoma 47.88 21.12 9 19498 83 110569709
Myositis 46.97 21.12 41 19466 31075 110538717
Papillary thyroid cancer 46.65 21.12 18 19489 2876 110566916
Abdominal discomfort 46.51 21.12 7 19500 393851 110175941
Stem cell transplant 45.65 21.12 20 19487 4407 110565385
Tumour lysis syndrome 45.32 21.12 40 19467 30761 110539031
Vascular device infection 45.25 21.12 31 19476 16481 110553311
Cytomegalovirus chorioretinitis 45.12 21.12 23 19484 7105 110562687
Product dose omission issue 45.01 21.12 3 19504 321779 110248013
Arthralgia 44.76 21.12 43 19464 779589 109790203
Acute myocardial infarction 44.65 21.12 64 19443 83713 110486079
Swelling 44.42 21.12 5 19502 351036 110218756
Deafness 43.99 21.12 37 19470 26672 110543120
Fall 43.97 21.12 26 19481 603456 109966336
Leukaemia 43.96 21.12 23 19484 7495 110562297
Basal ganglion degeneration 43.67 21.12 11 19496 425 110569367
Diarrhoea 43.19 21.12 85 19422 1139420 109430372
Lung disorder 43.17 21.12 97 19410 179950 110389842
Nasopharyngitis 42.25 21.12 9 19498 394352 110175440
Primary immunodeficiency syndrome 42.07 21.12 8 19499 79 110569713
Scleroderma 41.71 21.12 21 19486 6320 110563472
Pulmonary embolism 41.16 21.12 106 19401 214368 110355424
Combined immunodeficiency 41.14 21.12 9 19498 186 110569606
Anxiety 41.04 21.12 6 19501 345072 110224720
Restlessness 40.82 21.12 50 19457 56209 110513583
Sinusitis 40.82 21.12 3 19504 296685 110273107
Ischaemic stroke 40.69 21.12 43 19464 41220 110528572
Dizziness 40.66 21.12 38 19469 698155 109871637
Premature ageing 40.34 21.12 8 19499 100 110569692
Infusion related reaction 40.22 21.12 9 19498 381153 110188639
Blindness 39.66 21.12 40 19467 36319 110533473
Asthenospermia 39.34 21.12 7 19500 46 110569746
Uterine enlargement 39.00 21.12 12 19495 973 110568819
Taeniasis 38.59 21.12 7 19500 52 110569740
Hepatitis B reactivation 38.43 21.12 21 19486 7463 110562329
Tissue infiltration 38.32 21.12 12 19495 1031 110568761
Lung infiltration 38.28 21.12 33 19474 24595 110545197
Vulvovaginal inflammation 37.78 21.12 11 19496 738 110569054
Acute lymphocytic leukaemia 37.65 21.12 19 19488 5746 110564046
Tooth malformation 37.31 21.12 8 19499 150 110569642
Pruritus 37.08 21.12 29 19478 581531 109988261
Haemophagocytic lymphohistiocytosis 36.79 21.12 36 19471 31523 110538269
Cerebral infarction 35.89 21.12 45 19462 51793 110517999
Paraparesis 35.66 21.12 17 19490 4549 110565243
Anaesthesia 35.53 21.12 10 19497 594 110569198
Arterial thrombosis 35.14 21.12 15 19492 3104 110566688
Testicular cancer metastatic 35.12 21.12 7 19500 90 110569702
Hepatic enzyme increased 35.04 21.12 7 19500 320885 110248907
Aplasia 34.74 21.12 20 19487 7853 110561939
Mycobacterium avium complex infection 34.42 21.12 18 19489 5859 110563933
Autoimmune neutropenia 33.92 21.12 10 19497 701 110569091
Vascular access site occlusion 33.63 21.12 7 19500 113 110569679
Vena cava thrombosis 33.50 21.12 15 19492 3479 110566313
Abnormal DNA methylation 33.44 21.12 5 19502 8 110569784
Musculoskeletal stiffness 32.96 21.12 5 19502 279817 110289975
Organising pneumonia 32.69 21.12 24 19483 14219 110555573
Cytopenia 32.61 21.12 33 19474 30083 110539709
Testicular malignant teratoma 32.40 21.12 5 19502 11 110569781
Mucoepidermoid carcinoma of salivary gland 32.17 21.12 7 19500 141 110569651
Disease recurrence 31.75 21.12 46 19461 60738 110509054
Insomnia 31.66 21.12 12 19495 360578 110209214
Embolism arterial 31.53 21.12 12 19495 1847 110567945
Lymphadenopathy 31.45 21.12 47 19460 63788 110506004
Venoocclusive liver disease 31.29 21.12 24 19483 15183 110554609
Cerebral venous thrombosis 31.27 21.12 14 19493 3248 110566544
Skin fissures 30.59 21.12 29 19478 24429 110545363
Pneumonia salmonella 29.76 21.12 6 19501 82 110569710
Cardiomyopathy 29.67 21.12 33 19474 33492 110536300
Left ventricular dysfunction 29.65 21.12 28 19479 23465 110546327
Ichthyosis 29.60 21.12 7 19500 207 110569585
Hyperpyrexia 29.10 21.12 18 19489 8051 110561741
Wheezing 29.07 21.12 5 19502 255225 110314567
Guillain-Barre syndrome 29.03 21.12 20 19487 10724 110559068
Deep vein thrombosis 28.77 21.12 71 19436 139816 110429976
Psychogenic seizure 28.74 21.12 12 19495 2352 110567440
Peripheral sensorimotor neuropathy 28.73 21.12 14 19493 3929 110565863
Peripheral artery thrombosis 28.46 21.12 14 19493 4010 110565782
Neurotoxicity 28.20 21.12 36 19471 42171 110527621
Vocal cord inflammation 28.16 21.12 7 19500 256 110569536
Hepatitis G 28.11 21.12 6 19501 110 110569682
Peripheral T-cell lymphoma unspecified 27.59 21.12 9 19498 882 110568910
Chills 27.53 21.12 85 19422 190495 110379297
Blood pressure increased 27.45 21.12 6 19501 258367 110311425
Therapeutic product effect decreased 27.36 21.12 5 19502 244311 110325481
Pleural effusion 27.31 21.12 81 19426 177628 110392164
Depression 27.13 21.12 11 19496 317324 110252468
Cytomegalovirus infection 26.70 21.12 40 19467 54404 110515388
Pain in extremity 26.62 21.12 28 19479 487090 110082702
Muscle spasms 26.60 21.12 8 19499 278149 110291643
Death 26.52 21.12 52 19455 698817 109870975
Malignant transformation 26.43 21.12 10 19497 1515 110568277
Lymphopenia 26.43 21.12 34 19473 40136 110529656
Progressive multifocal leukoencephalopathy 26.39 21.12 27 19480 24929 110544863
Encephalitis viral 25.96 21.12 12 19495 2995 110566797
Overdose 25.72 21.12 5 19502 233789 110336003
Contusion 25.66 21.12 5 19502 233356 110336436
Oligohydramnios 25.61 21.12 13 19494 3981 110565811
Peritoneal gliomatosis 25.56 21.12 4 19503 10 110569782
Klebsiella infection 25.55 21.12 24 19483 19985 110549807
Abdominal pain upper 25.45 21.12 15 19492 349096 110220696
Blood pressure decreased 25.36 21.12 60 19447 115031 110454761
Ototoxicity 25.19 21.12 13 19494 4118 110565674
Infusion site joint movement impairment 25.03 21.12 4 19503 12 110569780
Hypertension 24.98 21.12 32 19475 510052 110059740
Diaphragm muscle weakness 24.74 21.12 6 19501 198 110569594
Headache 24.61 21.12 77 19430 882300 109687492
Subdural haemorrhage 24.60 21.12 15 19492 6543 110563249
Choriocarcinoma 24.56 21.12 5 19502 72 110569720
Splenic infarction 24.49 21.12 13 19494 4361 110565431
Bacterial infection 24.27 21.12 35 19472 46001 110523791
Inclusion body myositis 24.01 21.12 5 19502 81 110569711
Drug hypersensitivity 23.81 21.12 27 19480 454063 110115729
B precursor type acute leukaemia 23.69 21.12 7 19500 494 110569298
Meningoencephalitis amoebic 23.67 21.12 6 19501 238 110569554
Renal salt-wasting syndrome 23.62 21.12 8 19499 880 110568912
Spindle cell sarcoma 23.20 21.12 6 19501 258 110569534
Papilloma viral infection 23.16 21.12 10 19497 2128 110567664
Monoplegia 23.09 21.12 13 19494 4896 110564896
Transdifferentiation of neoplasm 22.73 21.12 5 19502 106 110569686
Hodgkin's disease nodular sclerosis 22.65 21.12 4 19503 25 110569767
Infusion site ulcer 22.65 21.12 4 19503 25 110569767
Mobility decreased 22.39 21.12 7 19500 237415 110332377
Hypochromic anaemia 22.23 21.12 11 19496 3190 110566602
Acanthamoeba infection 22.19 21.12 7 19500 616 110569176
Lung diffusion test decreased 22.10 21.12 9 19498 1656 110568136
Oropharyngeal squamous cell carcinoma 21.63 21.12 6 19501 338 110569454
Dysaesthesia 21.52 21.12 14 19493 6833 110562959
Lower respiratory tract infection 21.48 21.12 8 19499 243098 110326694
Immune thrombocytopenia 21.40 21.12 23 19484 22471 110547321
Confusional state 21.33 21.12 31 19476 468649 110101143
Posterior reversible encephalopathy syndrome 21.25 21.12 28 19479 33833 110535959

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01DC01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Other cytotoxic antibiotics
MeSH PA D000903 Antibiotics, Antineoplastic
MeSH PA D000970 Antineoplastic Agents
FDA EPC N0000180854 Cytoprotective Agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:64946 anti-HIV agent

Related Drugs by ATC class:

L01DC Other cytotoxic antibiotics 3 drugs
ixabepilonemitomycinplicamycin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diffuse non-Hodgkin's lymphoma, large cell indication 109969005
Hodgkin's disease indication 118599009
Non-Hodgkin's lymphoma indication 118601006
Malignant tumor of head and/or neck indication 255056009
Follicular non-Hodgkin's lymphoma indication 308121000
Malignant tumor of cervix indication 363354003 DOID:4362
Malignant tumor of penis indication 363516004 DOID:11615
International Federation of Gynecology and Obstetrics stage finding for vulvar carcinoma indication 385370007
Squamous cell carcinoma indication 402815007 DOID:1749
Pleural Malignant Effusions indication
Testicular Germ Cell Tumor indication
Mycosis fungoides off-label use 118618005
Ovarian Germ Cell Tumor Carcinoma off-label use




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Aspartyl/asparaginyl beta-hydroxylase Enzyme IC50 5.83 CHEMBL

External reference:

IDSource
D02177 KEGG_DRUG
4019637 VUID
N0000147730 NUI
4018135 VANDF
4019637 VANDF
CHEBI:3139 CHEBI
CHEMBL6067492 ChEMBL_ID
CHEMBL6067493 ChEMBL_ID
2721 INN_ID
9041-93-4 SECONDARY_CAS_RN
67763-87-5 SECONDARY_CAS_RN
DB00290 DRUGBANK_ID
40S1VHN69B UNII
1621 RXNORM
4293 MMSL
9784 MMSL
d00177 MMSL
002661 NDDF
004820 NDDF
009872 NDDF
15660006 SNOMEDCT_US
372843005 SNOMEDCT_US
703085003 SNOMEDCT_US
76591000 SNOMEDCT_US
C0005740 UMLSCUI
D001761 MESH_DESCRIPTOR_UI
5360373 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9240 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9241 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0323 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 21 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 0409-0332 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 21 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 16714-886 POWDER, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 16714-908 POWDER, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 23 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 61703-323 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 13 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 61703-332 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 13 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 63323-136 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 12 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 63323-137 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 12 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 71288-106 POWDER, FOR SOLUTION 15 [USPU] INTRAMUSCULAR ANDA 24 sections
Bleomycin HUMAN PRESCRIPTION DRUG LABEL 1 71288-107 POWDER, FOR SOLUTION 30 [USPU] INTRAMUSCULAR ANDA 24 sections